ELIAS Animal Health to Initate Clinical Evaluation of T-Cell Therapy for Limb-Sparing Canine Osteosarcoma
Shots:
- ELIAS Animal Health is planning to commence clinical evaluation of its T-cell therapy, ELIAS Cancer Immunotherapy (ECI), combined with a new adj., as a limb-sparing treatment of appendicular osteosarcoma in large-breed dogs
- The study will explore new treatment possibilities with the combination that may avoid amputation, enhancing the quality of life in dogs. ECI has also shown favorable outcomes in prior canine osteosarcoma trials and reached a milestone in product licensure
- The study will be carried out in partnership with Dr. Jeffrey Bryan and Dr. Megan Mickelson at the University of Missouri plus will be sponsored by a grant from the Morris Animal Foundation
Ref: PR Newswire | Image: ELIAS Animal Health
Related News:- ELIAS Animal Health Reports Results from the (ECI-OSA-04) Study of ELIAS Cancer Immunotherapy (ECI) for Treating Bone Cancer in Dogs
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
